Tourette Syndrome: A Look at Today's Best Treatments

Tourette syndrome (TS) is more than just a childhood phase of twitching or making sounds—it's a chronic neurodevelopmental condition that can disrupt daily functioning and emotional well-being. Characterized by both motor and vocal tics that begin before age 18 and last for more than a year, Tourette's often brings along other challenges like ADHD, obsessive-compulsive disorder (OCD), and anxiety. While some kids see symptoms lessen as they age, others need long-term, individualized treatment plans to manage both the tics and associated psychiatric conditions.
Tourette syndrome is diagnosed when an individual has at least two motor tics and one vocal tic for more than 12 months, with onset before age 18 [1]. These tics are sudden, repetitive, and involuntary—for example, blinking, throat clearing, or shoulder shrugging. A helpful diagnostic clue is that people with TS can often suppress their tics briefly, unlike those with habit cough or psychogenic cough [1].
Differentiating TS from other movement or psychiatric disorders is key, especially since tics can wax and wane in intensity. That fluctuation, combined with the ability to voluntarily hold back tics for short periods, helps set Tourette's apart from conditions like dystonia or chorea.
Behavioral therapy is the foundation of TS treatment, and CBIT is the gold standard. This structured approach combines habit reversal training with relaxation techniques and functional intervention strategies. CBIT helps individuals recognize premonitory urges—the sensations that precede tics—and teaches them to respond with competing behaviors that prevent the tic.
CBIT has been shown to be effective across different delivery formats. A 2024 review found it worked in both in-person and telehealth settings—even when ADHD or OCD were present [4]. In fact, recent studies show that tele-CBIT sessions are almost as effective as in-office visits [5], making it a convenient option for families with busy schedules or living far from specialists.
Medications like clonidine and guanfacine are often used for kids with mild to moderate tics—especially when ADHD is also present. These medications work on the brain's norepinephrine pathways to reduce hyperactivity and impulsivity which in turn can reduce tic severity.
Their appeal is their safety profile. Compared to antipsychotics, alpha-2 agonists are less likely to cause serious side effects, making them a good starting point for young patients [2] [3].
When behavioral therapy and alpha-agonists don't work, antipsychotic medications may be added. These drugs target dopamine pathways—known to be involved in tic generation—but come with trade-offs.
Aripiprazole and risperidone are commonly prescribed because they are better tolerated than older drugs like haloperidol. Meanwhile pimozide, a dopamine receptor blocker, has shown better outcomes than haloperidol in clinical trials [1].
For individuals with focal tics—like persistent eye blinking or neck movements—botulinum toxin injections can provide targeted relief by weakening overactive muscles [6].
Despite their effectiveness, antipsychotics require close monitoring. Side effects like sedation, weight gain, and movement disorders (e.g., tardive dyskinesia) can emerge especially with long-term use. Clinicians must weigh the benefits of symptom relief against the risk of side effects and adjust treatment accordingly [3].
For the small percentage of individuals with treatment-refractory TS, Deep Brain Stimulation (DBS) may be considered. DBS involves surgically implanting electrodes into specific brain regions to modulate abnormal activity. While still relatively rare and not standard care, DBS has shown promising results in reducing severe tics in select patients [6].
Beyond medical interventions, holistic care is key. Support groups, patient education and school-based accommodations—like extended test times or breaks during class—can make a big difference in a child's social and academic success.
TS isn't just about the tics—it's about the whole person. Comorbidities like OCD, ADHD, and anxiety often impact daily life more than the tics themselves. So treatment plans must be individualized and medication choices should consider these overlapping conditions [2].
Clinicians must also distinguish tics from other movement disorders. Features like premonitory urges, voluntary suppression and the episodic nature of tics can help differentiate TS from other hyperkinetic disorders [1].
Tourette syndrome may be lifelong but it doesn't have to be life defining. With the right combination of behavioral therapy, medication, support and education most people can manage their symptoms and live well. As research advances—especially in digital therapy delivery and neuromodulation—there's more hope for more personalized, accessible and effective treatments for people with TS.
[1] Irwin, R. S., Glomb, W. B., & Chang, A. B. (2006). Habit cough, tic cough, and psychogenic cough in adult and pediatric populations: ACCP evidence-based clinical practice guidelines. Chest, 129(1 Suppl), 174S–179S. https://doi.org/10.1378/chest.129.1_suppl.174S
[2] Egolf, A., & Coffey, B. J. (2014). Current pharmacotherapeutic approaches for the treatment of Tourette syndrome. Drugs of today (Barcelona, Spain : 1998), 50(2), 159–179. https://doi.org/10.1358/dot.2014.50.2.2097801
[3] Whittington, C., Pennant, M., Kendall, T., Glazebrook, C., Trayner, P., Groom, M., Hedderly, T., Heyman, I., Jackson, G., Jackson, S., Murphy, T., Rickards, H., Robertson, M., Stern, J., & Hollis, C. (2016). Practitioner Review: Treatments for Tourette syndrome in children and young people - a systematic review. Journal of child psychology and psychiatry, and allied disciplines, 57(9), 988–1004. https://doi.org/10.1111/jcpp.12556
[4] Kohler, K., Rosen, N., & Piacentini, J. (2025). Description, Implementation, and Efficacy of the Comprehensive Behavioral Intervention for Tics as First-Line Treatment for Tourette and Other Tic Disorders. Journal of child and adolescent psychopharmacology, 35(3), 126–134. https://doi.org/10.1089/cap.2024.0023
[5] Morand-Beaulieu, S., Szejko, N., Fletcher, J., & Pringsheim, T. (2024). Behavioural Therapy for tic disorders: a comprehensive review of the literature. Expert review of neurotherapeutics, 24(12), 1181–1191. https://doi.org/10.1080/14737175.2024.2405740
[6] Billnitzer, A., & Jankovic, J. (2020). Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 17(4), 1681–1693. https://doi.org/10.1007/s13311-020-00914-6

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Bloomberg

13 hours ago

• Bloomberg

Not All Ritalin Is Created Equal: Why Some Generics Fail to Work

Stanford University researchers have discovered why some people with attention deficit hyperactivity disorder may do well on their medicine for a while but struggle down the road. Researchers tested how generic Ritalin and other versions of the drug known as methylphenidate dissolve and found some dissipated much more quickly or slowly than they should have, according to a study, the final version of which is set to be published in the Journal of the American Academy of Child and Adolescent Psychiatry.

CBS News

16 hours ago

• CBS News

Dog on Colorado's Anschutz Medical Campus leading way on novel obsessive-compulsive disorder therapy treatment

It has become common for dogs to be used for a variety of behavioral health solutions, including those like post-traumatic stress disorder, for instance. But at the University of Colorado Anschutz Medical Campus, there is a single dog that is being used in a rather unique way: helping patients with obsessive compulsive disorder, or OCD, manage their symptoms. Cate Rush, a social work fellow who works on the campus, has had Otis the Bernese Mountain Dog since her junior year of her undergraduate studies. He's helped in her in a variety of ways throughout her adult life, and she's now using him to help her patients as well. Cate Rush with Otis CBS "I just feel like it's so special that he's able to do something that humans cannot," she said. Otis is a trained therapy dog but works with a specific set of clients. Most of the patients that come see Cate have OCD. "Therapy dogs aren't commonly used for OCD so it's been a bit of a learning experience how to use him," she said. The research on the use of dogs for OCD patients is still evolving, as is most of the research around therapy dogs in general. It's only been since the turn of the 2000s that having dogs used as aids for behavioral health solutions has become more common. But it's rare to see one that is working with OCD patients. Otis is the only dog of his kind on the medical campus in Aurora. Obsessive-compulsive disorder currently affects 2.5% of the United States population and can be treated with what is called exposure and response prevention therapy, or ERPT. It usually involves exposing patients to things that trigger their obsessive behaviors while giving them tools to help prevent them from engaging in their typical compulsions. A 2010 study by the University of Pennsylvania, cited in the National Institute of Health, showed that ERPT can significantly reduce OCD symptoms in up to 80% of patients. CBS That's where Otis comes in. He can help in a variety of ways, as a supportive and helpful sidekick to those being exposed to triggering things or situations or, in some cases, being a walking exposure therapy himself. "There are a lot of patients who might have contamination fears," Rush said, "They can use him in exposure so I've had patients touch his paws or rub his belly." "I had a patient and one of her final exposures in the IOP -- the intensive outpatient program -- was to high five Otis and that was really sweet," she added. While Otis isn't part of any official research at Anschutz just yet, his presence signals an evolving approach to behavioral health solutions. One wag at a time.

Yahoo

17 hours ago

• Yahoo

ADHD waiting list led to rise in unregulated private providers

NHS waiting lists for ADHD diagnosis and support have led to a 'significant growth in the use of private providers that are not regulated', a taskforce has said. The ADHD taskforce, commissioned by NHS England with the support of the Government, has published an interim report saying the system for diagnosing and managing ADHD needs to be overhauled. At the moment, ADHD assessment and treatment in England is provided by highly specialised doctors in secondary care. But the report warned: 'Inability to access NHS services has led to a significant growth in the use of private providers that are not regulated, resulting in two-tier access to services, diagnosis and treatment; one for those who can pay and another for those who cannot. 'This drives health inequalities and links to disproportionate impacts and outcomes in the education and justice systems, employment and health.' Experts behind the study said waiting times for NHS ADHD services 'have escalated and are unacceptably long' and demand on services is 'very likely' to continue to rise. The taskforce concluded that ADHD is not solely the remit of the NHS and other health providers, with schools being vital for identifying and meeting needs at an early stage. And while a clinical diagnosis of ADHD via the NHS is required if a person needs medication, early support can still be provided to others. The report said: 'We need timely recognition and early support of suspected ADHD and neurodivergence across all settings. 'This is especially important in schools and the early years, to prevent adverse impacts and costly outcomes in the future. This should be needs-led and not require a clinical diagnosis.' The report also suggested there is no evidence of over-diagnosis of ADHD in the UK. It argued: 'England and the rest of the UK have much lower service recognition and treatment rates of ADHD diagnosis compared with other European countries. 'Recent data show a very high level of under-recognition and under-treatment of strictly diagnosed ADHD, with significant inequalities in access to care.' The report also addressed concerns about potential 'over-medicalisation and over-diagnosis', including worries that people are self-diagnosing ADHD based on information from social media. However, the report, said that 'currently there is no good evidence on what percentage of those waiting to see a clinician have self-diagnosed ADHD using social media and eventually meet or do not meet ADHD diagnostic criteria after a high-quality assessment. 'We only know currently that in England, recognised rates of ADHD are lower than the expected prevalence of ADHD.' Currently, the estimated economic costs of not treating ADHD are around £17 billion to the UK economy, the report went on. This includes through lower tax contributions, people needing state benefits and more likely to be not in education, employment or training, or who are long-term unemployed. 'Many of these costs are avoidable, as with appropriate, early support, people with ADHD can thrive,' it said. Professor Anita Thapar, chair of the ADHD Taskforce, said: 'The recommendations put forward by the taskforce will require action across Government and cross-sector organisations to make the necessary changes to improve the lives of people with ADHD. 'We need to get this right, to make sure people get early diagnosis and support, not just in the NHS but across society.' Dr Adrian James, NHS England's medical director for mental health and neurodiversity, said: 'We know that too many people with ADHD have been waiting for too long for support, which is why we launched the taskforce last year to help respond to the significant growth in the need for care. 'It is clear that much more needs to be done to improve ADHD assessment and care in England and ensure people can get a timely diagnosis, and we welcome the findings from the interim report, and look forward to its final conclusions later this year.' The NHS has launched publicly-available data collection on ADHD referrals and waiting times to help local teams better understand how they are performing. By March 2026, the Government also aims for six in 10 pupils to have access to a mental health support team in school.